Epigenomics AG is a molecular diagnostics company headquartered in Berlin, Germany, specializing in the development and commercialization of epigenetic biomarker assays for the early detection of cancer. Founded in 1998, the firm leverages proprietary DNA methylation technology to identify tumor-derived DNA fragments in body fluids, with the aim of providing minimally invasive screening and diagnostic tests that improve patient outcomes.
The company’s flagship product, Epi proColon, is a blood-based screening test designed to detect methylated SEPT9 DNA, an established biomarker for colorectal cancer. This assay has been approved for use in multiple markets, including the European Union and the United States, and offers an alternative to traditional fecal screening methods. In addition to colorectal applications, Epigenomics is advancing a pipeline of next-generation assays targeting other indications such as lung and pancreatic cancer, in collaboration with academic and industry partners.
Epigenomics serves a global customer base through a network of distribution and licensing agreements, with a focus on European and North American clinical laboratories and healthcare providers. The company maintains strategic partnerships across Asia and the Middle East to facilitate market entry and local regulatory approval. Its products are supported by extensive clinical studies and real-world performance data, reinforcing its position in the oncology diagnostics landscape.
Under the guidance of an experienced management team with deep expertise in molecular biology, oncology research and commercial diagnostics, Epigenomics continues to expand its R&D capabilities and global footprint. The board of directors and scientific advisory board include leading experts in cancer epigenetics, ensuring that the company remains at the forefront of innovation in non-invasive cancer testing and translational biomarker discovery.
AI Generated. May Contain Errors.
